Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Pharma
FDA broadens label for Sarepta's Duchenne gene therapy Elevidys
The FDA has expanded the label for Sarepta's Duchenne muscular dystrophy gene therapy Elevidys to all patients ages 4 and older.
Kevin Dunleavy
Jun 21, 2024 7:51am
Italfarmaco wins FDA's blessing for nonsteroidal DMD therapy
Mar 22, 2024 11:05am
PTC, after rejections, will try again with Translarna at the FDA
Mar 19, 2024 10:10am
Elevidys gains steam amid Sarepta's efforts to widen FDA label
Feb 29, 2024 4:11pm
Sarepta's Elevidys expansion bid gets fast review without adcomm
Feb 16, 2024 11:05am
NS Pharma launches ‘Duchenne Heroes’ campaign
Nov 27, 2023 10:08am
